title: [Clinical study of the area under the blood concentration-time curve of targeting intra-arterial infusion chemotherapy with nedaplatin for primary oral cancer].
abstract: We treated oral cancer using a targeting intra-arterial infusion chemotherapy with CDGP (nedaplatin); dosages were determined by the original formula. We compared the expected AUC (area under the curve) with the actual AUC in primary oral cancer cases to assess the optimal dosage of CDGP for intra-arterial chemotherapy and to study relevance of AUC, effectiveness of independent chemotherapy and side effects. Eleven cases were treated at the Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Kagawa Medical University, from October 1998 to June 2002. The results are as follows. 1) A correlation was seen between the AUC and degree of thrombocytopenia. 2) AUC may reveal renal function, especially for GFR. 3) The response rate of the targeted intra-arterial infusion chemotherapy with CDGP was remarkably high and serious side effects were not observed. It appears that the set-up of the optimum dose should be decided based on the actual AUC. 4) There was about a 4/3 difference between the value of the expected AUC and the actual AUC. The equation for dosages based on the actual AUC needs to be studied further.
authors.affiliation: Dept. of Oral and Maxillofacial Surgery, Faculty of Medicine, Kagawa Medical University.
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Ohbayashi
authors.forename: Minoru
authors.initials: M
authors.lastname: Miyake
authors.forename: Akinori
authors.initials: A
authors.lastname: Iwasaki
authors.forename: Takaaki
authors.initials: T
authors.lastname: Ogawa
authors.forename: Shunichiro
authors.initials: S
authors.lastname: Nagahata
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Toyama
authors.forename: Motoomi
authors.initials: M
authors.lastname: Ohkawa
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019540:Area Under Curve; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005919:Glomerular Filtration Rate; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D009944:Organoplatinum Compounds / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D009944:Organoplatinum Compounds; C053989:nedaplatin; D005472:Fluorouracil